Loading…

Evaluation of Xpert MTB/RIF assay performance in the diagnosis of abdominal tuberculosis

Background/Aims: The use of genetic probes for the diagnosis of pulmonary tuberculosis (TB) has been well described. However, the role of these assays in the diagnosis of intestinal tuberculosis is unclear. We therefore assessed the diagnostic utility of the Xpert Mycobacterium tuberculosis/rifampic...

Full description

Saved in:
Bibliographic Details
Published in:Intestinal Research 2017, 15(2), , pp.187-194
Main Authors: Kumar, Suraj, Bopanna, Sawan, Kedia, Saurabh, Mouli, Pratap, Dhingra, Rajan, Padhan, Rajesh, Kohli, Mikashmi, Chaubey, Jigyasa, Sharma, Rohini, Das, Prasenjit, Dattagupta, S, Makharia, Govind, Sharma, SK, Ahuja, Vineet
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c496t-e8f34bdb759558d66c05a1e2b6664cc7499857f97f0228fc2750c10fc18ff8613
cites cdi_FETCH-LOGICAL-c496t-e8f34bdb759558d66c05a1e2b6664cc7499857f97f0228fc2750c10fc18ff8613
container_end_page 194
container_issue 2
container_start_page 187
container_title Intestinal Research
container_volume 15
creator Kumar, Suraj
Bopanna, Sawan
Kedia, Saurabh
Mouli, Pratap
Dhingra, Rajan
Padhan, Rajesh
Kohli, Mikashmi
Chaubey, Jigyasa
Sharma, Rohini
Das, Prasenjit
Dattagupta, S
Makharia, Govind
Sharma, SK
Ahuja, Vineet
description Background/Aims: The use of genetic probes for the diagnosis of pulmonary tuberculosis (TB) has been well described. However, the role of these assays in the diagnosis of intestinal tuberculosis is unclear. We therefore assessed the diagnostic utility of the Xpert Mycobacterium tuberculosis/rifampicin (MTB/RIF) assay, and estimated the prevalence of multidrug-resistant (MDR) TB in the Indian population.Methods: Of 99 patients recruited, 37 had intestinal TB; two control groups comprised 43 with Crohn's disease (CD) and 19 with irritable bowel syndrome. Colonoscopy was performed before starting any therapy; mucosal biopsies were subjected to histopathology, acid-fast bacilli staining, Lowenstein-Jensen culture, and nucleic acid amplification testing using the Xpert MTB/RIF assay. Patients were followed up for 6 months to confirm the diagnosis and response to therapy. A composite reference standard was used for diagnosis of TB and assessment of the diagnostic utility of the Xpert MTB/RIF assay.Results: Of 37 intestinal TB patients, the Xpert MTB/RIF assay was positive in three of 37 (8.1%), but none had MDR-TB. The sensitivity, specificity, positive predictive value, and negative predictive value of the Xpert MTB/RIF assay was 8.1%, 100%, 100%, and, 64.2%, respectively.Conclusions: The Xpert MTB/RIF assay has low sensitivity but high specificity for intestinal TB, and may be helpful in endemic tuberculosis areas, when clinicians are faced with difficulty differentiating TB and CD. Based on the Xpert MTB/RIF assay, the prevalence of intestinal MDR-TB is low in the Indian population.
doi_str_mv 10.5217/ir.2017.15.2.187
format article
fullrecord <record><control><sourceid>nrf_doaj_</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_1363715</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_8d3e2afd638d4cabbf9504c119c62f6a</doaj_id><sourcerecordid>oai_kci_go_kr_ARTI_1363715</sourcerecordid><originalsourceid>FETCH-LOGICAL-c496t-e8f34bdb759558d66c05a1e2b6664cc7499857f97f0228fc2750c10fc18ff8613</originalsourceid><addsrcrecordid>eNpVkc1LHEEQxZuQoIvx7nGuOczY1d99CRjRuKAEZAPemv5cO85OLz2zgv99ZndF8PSgXr0fVTyELgB3nIC8zLUjGGQHvCMdKPkFLQhRqgXNxVe0AK5VqwHjU3Q-jtlhxiQDTekJOiWKE6KZWqCnm1fb7-yUy9CU1DxtY52ah9Wvy8flbWPH0b418yiVurGDj00emuk5NiHb9VDGPO4z1oWyyYPtm2nnYvW7fu98R9-S7cd4_q5n6O_tzer6rr3_83t5fXXfeqbF1EaVKHPBSa45V0EIj7mFSJwQgnkvmdaKy6RlwvNzyRPJsQecPKiUlAB6hn4cuUNN5sVnU2w-6LqYl2quHldLA1RQCXzeXR53Q7H_zLbmja1vh8BhUOra2Dpl30ejAo3EpiCoCsxb55LmmHkA7QVJws6sn0fWduc2Mfg4TNX2n6CfnSE_zze9Gs4oxoBnAD4CfC3jWGP6yAI2-4JNrmZfsAFuiJkLpv8BdLKYQw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Evaluation of Xpert MTB/RIF assay performance in the diagnosis of abdominal tuberculosis</title><source>PubMed (Medline)</source><creator>Kumar, Suraj ; Bopanna, Sawan ; Kedia, Saurabh ; Mouli, Pratap ; Dhingra, Rajan ; Padhan, Rajesh ; Kohli, Mikashmi ; Chaubey, Jigyasa ; Sharma, Rohini ; Das, Prasenjit ; Dattagupta, S ; Makharia, Govind ; Sharma, SK ; Ahuja, Vineet</creator><creatorcontrib>Kumar, Suraj ; Bopanna, Sawan ; Kedia, Saurabh ; Mouli, Pratap ; Dhingra, Rajan ; Padhan, Rajesh ; Kohli, Mikashmi ; Chaubey, Jigyasa ; Sharma, Rohini ; Das, Prasenjit ; Dattagupta, S ; Makharia, Govind ; Sharma, SK ; Ahuja, Vineet</creatorcontrib><description>Background/Aims: The use of genetic probes for the diagnosis of pulmonary tuberculosis (TB) has been well described. However, the role of these assays in the diagnosis of intestinal tuberculosis is unclear. We therefore assessed the diagnostic utility of the Xpert Mycobacterium tuberculosis/rifampicin (MTB/RIF) assay, and estimated the prevalence of multidrug-resistant (MDR) TB in the Indian population.Methods: Of 99 patients recruited, 37 had intestinal TB; two control groups comprised 43 with Crohn's disease (CD) and 19 with irritable bowel syndrome. Colonoscopy was performed before starting any therapy; mucosal biopsies were subjected to histopathology, acid-fast bacilli staining, Lowenstein-Jensen culture, and nucleic acid amplification testing using the Xpert MTB/RIF assay. Patients were followed up for 6 months to confirm the diagnosis and response to therapy. A composite reference standard was used for diagnosis of TB and assessment of the diagnostic utility of the Xpert MTB/RIF assay.Results: Of 37 intestinal TB patients, the Xpert MTB/RIF assay was positive in three of 37 (8.1%), but none had MDR-TB. The sensitivity, specificity, positive predictive value, and negative predictive value of the Xpert MTB/RIF assay was 8.1%, 100%, 100%, and, 64.2%, respectively.Conclusions: The Xpert MTB/RIF assay has low sensitivity but high specificity for intestinal TB, and may be helpful in endemic tuberculosis areas, when clinicians are faced with difficulty differentiating TB and CD. Based on the Xpert MTB/RIF assay, the prevalence of intestinal MDR-TB is low in the Indian population.</description><identifier>ISSN: 1598-9100</identifier><identifier>EISSN: 2288-1956</identifier><identifier>DOI: 10.5217/ir.2017.15.2.187</identifier><identifier>PMID: 28522948</identifier><language>eng</language><publisher>Korean Association for the Study of Intestinal Diseases</publisher><subject>Crohn disease ; Original ; Tuberculosis, multidrug-resistant ; Xpert MTB/RIF assay ; 내과학</subject><ispartof>Intestinal research, 2017, 15(2), , pp.187-194</ispartof><rights>Copyright 2017. Korean Association for the Study of Intestinal Diseases. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c496t-e8f34bdb759558d66c05a1e2b6664cc7499857f97f0228fc2750c10fc18ff8613</citedby><cites>FETCH-LOGICAL-c496t-e8f34bdb759558d66c05a1e2b6664cc7499857f97f0228fc2750c10fc18ff8613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5430010/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5430010/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002218877$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Kumar, Suraj</creatorcontrib><creatorcontrib>Bopanna, Sawan</creatorcontrib><creatorcontrib>Kedia, Saurabh</creatorcontrib><creatorcontrib>Mouli, Pratap</creatorcontrib><creatorcontrib>Dhingra, Rajan</creatorcontrib><creatorcontrib>Padhan, Rajesh</creatorcontrib><creatorcontrib>Kohli, Mikashmi</creatorcontrib><creatorcontrib>Chaubey, Jigyasa</creatorcontrib><creatorcontrib>Sharma, Rohini</creatorcontrib><creatorcontrib>Das, Prasenjit</creatorcontrib><creatorcontrib>Dattagupta, S</creatorcontrib><creatorcontrib>Makharia, Govind</creatorcontrib><creatorcontrib>Sharma, SK</creatorcontrib><creatorcontrib>Ahuja, Vineet</creatorcontrib><title>Evaluation of Xpert MTB/RIF assay performance in the diagnosis of abdominal tuberculosis</title><title>Intestinal Research</title><description>Background/Aims: The use of genetic probes for the diagnosis of pulmonary tuberculosis (TB) has been well described. However, the role of these assays in the diagnosis of intestinal tuberculosis is unclear. We therefore assessed the diagnostic utility of the Xpert Mycobacterium tuberculosis/rifampicin (MTB/RIF) assay, and estimated the prevalence of multidrug-resistant (MDR) TB in the Indian population.Methods: Of 99 patients recruited, 37 had intestinal TB; two control groups comprised 43 with Crohn's disease (CD) and 19 with irritable bowel syndrome. Colonoscopy was performed before starting any therapy; mucosal biopsies were subjected to histopathology, acid-fast bacilli staining, Lowenstein-Jensen culture, and nucleic acid amplification testing using the Xpert MTB/RIF assay. Patients were followed up for 6 months to confirm the diagnosis and response to therapy. A composite reference standard was used for diagnosis of TB and assessment of the diagnostic utility of the Xpert MTB/RIF assay.Results: Of 37 intestinal TB patients, the Xpert MTB/RIF assay was positive in three of 37 (8.1%), but none had MDR-TB. The sensitivity, specificity, positive predictive value, and negative predictive value of the Xpert MTB/RIF assay was 8.1%, 100%, 100%, and, 64.2%, respectively.Conclusions: The Xpert MTB/RIF assay has low sensitivity but high specificity for intestinal TB, and may be helpful in endemic tuberculosis areas, when clinicians are faced with difficulty differentiating TB and CD. Based on the Xpert MTB/RIF assay, the prevalence of intestinal MDR-TB is low in the Indian population.</description><subject>Crohn disease</subject><subject>Original</subject><subject>Tuberculosis, multidrug-resistant</subject><subject>Xpert MTB/RIF assay</subject><subject>내과학</subject><issn>1598-9100</issn><issn>2288-1956</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkc1LHEEQxZuQoIvx7nGuOczY1d99CRjRuKAEZAPemv5cO85OLz2zgv99ZndF8PSgXr0fVTyELgB3nIC8zLUjGGQHvCMdKPkFLQhRqgXNxVe0AK5VqwHjU3Q-jtlhxiQDTekJOiWKE6KZWqCnm1fb7-yUy9CU1DxtY52ah9Wvy8flbWPH0b418yiVurGDj00emuk5NiHb9VDGPO4z1oWyyYPtm2nnYvW7fu98R9-S7cd4_q5n6O_tzer6rr3_83t5fXXfeqbF1EaVKHPBSa45V0EIj7mFSJwQgnkvmdaKy6RlwvNzyRPJsQecPKiUlAB6hn4cuUNN5sVnU2w-6LqYl2quHldLA1RQCXzeXR53Q7H_zLbmja1vh8BhUOra2Dpl30ejAo3EpiCoCsxb55LmmHkA7QVJws6sn0fWduc2Mfg4TNX2n6CfnSE_zze9Gs4oxoBnAD4CfC3jWGP6yAI2-4JNrmZfsAFuiJkLpv8BdLKYQw</recordid><startdate>20170401</startdate><enddate>20170401</enddate><creator>Kumar, Suraj</creator><creator>Bopanna, Sawan</creator><creator>Kedia, Saurabh</creator><creator>Mouli, Pratap</creator><creator>Dhingra, Rajan</creator><creator>Padhan, Rajesh</creator><creator>Kohli, Mikashmi</creator><creator>Chaubey, Jigyasa</creator><creator>Sharma, Rohini</creator><creator>Das, Prasenjit</creator><creator>Dattagupta, S</creator><creator>Makharia, Govind</creator><creator>Sharma, SK</creator><creator>Ahuja, Vineet</creator><general>Korean Association for the Study of Intestinal Diseases</general><general>대한장연구학회</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope><scope>ACYCR</scope></search><sort><creationdate>20170401</creationdate><title>Evaluation of Xpert MTB/RIF assay performance in the diagnosis of abdominal tuberculosis</title><author>Kumar, Suraj ; Bopanna, Sawan ; Kedia, Saurabh ; Mouli, Pratap ; Dhingra, Rajan ; Padhan, Rajesh ; Kohli, Mikashmi ; Chaubey, Jigyasa ; Sharma, Rohini ; Das, Prasenjit ; Dattagupta, S ; Makharia, Govind ; Sharma, SK ; Ahuja, Vineet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c496t-e8f34bdb759558d66c05a1e2b6664cc7499857f97f0228fc2750c10fc18ff8613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Crohn disease</topic><topic>Original</topic><topic>Tuberculosis, multidrug-resistant</topic><topic>Xpert MTB/RIF assay</topic><topic>내과학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kumar, Suraj</creatorcontrib><creatorcontrib>Bopanna, Sawan</creatorcontrib><creatorcontrib>Kedia, Saurabh</creatorcontrib><creatorcontrib>Mouli, Pratap</creatorcontrib><creatorcontrib>Dhingra, Rajan</creatorcontrib><creatorcontrib>Padhan, Rajesh</creatorcontrib><creatorcontrib>Kohli, Mikashmi</creatorcontrib><creatorcontrib>Chaubey, Jigyasa</creatorcontrib><creatorcontrib>Sharma, Rohini</creatorcontrib><creatorcontrib>Das, Prasenjit</creatorcontrib><creatorcontrib>Dattagupta, S</creatorcontrib><creatorcontrib>Makharia, Govind</creatorcontrib><creatorcontrib>Sharma, SK</creatorcontrib><creatorcontrib>Ahuja, Vineet</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><collection>Korean Citation Index</collection><jtitle>Intestinal Research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kumar, Suraj</au><au>Bopanna, Sawan</au><au>Kedia, Saurabh</au><au>Mouli, Pratap</au><au>Dhingra, Rajan</au><au>Padhan, Rajesh</au><au>Kohli, Mikashmi</au><au>Chaubey, Jigyasa</au><au>Sharma, Rohini</au><au>Das, Prasenjit</au><au>Dattagupta, S</au><au>Makharia, Govind</au><au>Sharma, SK</au><au>Ahuja, Vineet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of Xpert MTB/RIF assay performance in the diagnosis of abdominal tuberculosis</atitle><jtitle>Intestinal Research</jtitle><date>2017-04-01</date><risdate>2017</risdate><volume>15</volume><issue>2</issue><spage>187</spage><epage>194</epage><pages>187-194</pages><issn>1598-9100</issn><eissn>2288-1956</eissn><abstract>Background/Aims: The use of genetic probes for the diagnosis of pulmonary tuberculosis (TB) has been well described. However, the role of these assays in the diagnosis of intestinal tuberculosis is unclear. We therefore assessed the diagnostic utility of the Xpert Mycobacterium tuberculosis/rifampicin (MTB/RIF) assay, and estimated the prevalence of multidrug-resistant (MDR) TB in the Indian population.Methods: Of 99 patients recruited, 37 had intestinal TB; two control groups comprised 43 with Crohn's disease (CD) and 19 with irritable bowel syndrome. Colonoscopy was performed before starting any therapy; mucosal biopsies were subjected to histopathology, acid-fast bacilli staining, Lowenstein-Jensen culture, and nucleic acid amplification testing using the Xpert MTB/RIF assay. Patients were followed up for 6 months to confirm the diagnosis and response to therapy. A composite reference standard was used for diagnosis of TB and assessment of the diagnostic utility of the Xpert MTB/RIF assay.Results: Of 37 intestinal TB patients, the Xpert MTB/RIF assay was positive in three of 37 (8.1%), but none had MDR-TB. The sensitivity, specificity, positive predictive value, and negative predictive value of the Xpert MTB/RIF assay was 8.1%, 100%, 100%, and, 64.2%, respectively.Conclusions: The Xpert MTB/RIF assay has low sensitivity but high specificity for intestinal TB, and may be helpful in endemic tuberculosis areas, when clinicians are faced with difficulty differentiating TB and CD. Based on the Xpert MTB/RIF assay, the prevalence of intestinal MDR-TB is low in the Indian population.</abstract><pub>Korean Association for the Study of Intestinal Diseases</pub><pmid>28522948</pmid><doi>10.5217/ir.2017.15.2.187</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1598-9100
ispartof Intestinal research, 2017, 15(2), , pp.187-194
issn 1598-9100
2288-1956
language eng
recordid cdi_nrf_kci_oai_kci_go_kr_ARTI_1363715
source PubMed (Medline)
subjects Crohn disease
Original
Tuberculosis, multidrug-resistant
Xpert MTB/RIF assay
내과학
title Evaluation of Xpert MTB/RIF assay performance in the diagnosis of abdominal tuberculosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T05%3A09%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-nrf_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20Xpert%20MTB/RIF%20assay%20performance%20in%20the%20diagnosis%20of%20abdominal%20tuberculosis&rft.jtitle=Intestinal%20Research&rft.au=Kumar,%20Suraj&rft.date=2017-04-01&rft.volume=15&rft.issue=2&rft.spage=187&rft.epage=194&rft.pages=187-194&rft.issn=1598-9100&rft.eissn=2288-1956&rft_id=info:doi/10.5217/ir.2017.15.2.187&rft_dat=%3Cnrf_doaj_%3Eoai_kci_go_kr_ARTI_1363715%3C/nrf_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c496t-e8f34bdb759558d66c05a1e2b6664cc7499857f97f0228fc2750c10fc18ff8613%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/28522948&rfr_iscdi=true